Multiple Clinical Trial Data for Elecoglipron (AZD5004/ECC5004), an Oral GLP-1 Receptor Agonist, to be Presented at ADA 2026
Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions, today announced that data from a Phase 1b study conducted in China evaluating elecoglipron (AZD5004/ECC5004), an oral small-molecule GLP-1 receptor agonist, will be presented in a late-breaking poster presentation at the 2026 Scientific Sessions of the American Diabetes Association® (ADA). The ADA’s 2026 Scientific Sessions will take place June 5-8 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.
In addition, AstraZeneca, who has in-licensed global rights to elecoglipron outside Greater China, will present Phase 2b data from two global studies of elecoglipron during an ADA symposium.
"We are excited to showcase the rapid progress of elecoglipron at the ADA’s 2026 Scientific Sessions, marking a pivotal moment for Eccogene on the global stage," said Jingye Zhou, Ph.D., Chief Executive Officer of Eccogene. "The presentation of our late-breaking Phase 1b data alongside AstraZeneca’s Phase 2b symposium underscores the momentum behind this program. It is a testament to our shared commitment to advancing elecoglipron to deliver clinically meaningful results for patients worldwide."
